We are live on ! Find out more
GILD icon

Gilead Sciences

1,263 hedge funds and large institutions have $116B invested in Gilead Sciences in 2014 Q2 according to their latest regulatory filings, with 163 funds opening new positions, 527 increasing their positions, 461 reducing their positions, and 83 closing their positions.

New
Increased
Maintained
Reduced
Closed

96% more first-time investments, than exits

New positions opened: 163 | Existing positions closed: 83

46% more funds holding in top 10

Funds holding in top 10: 112164 (+52)

14% more repeat investments, than reductions

Existing positions increased: 527 | Existing positions reduced: 461

6% more funds holding

Funds holding: 1,1891,263 (+74)

0% less capital invested

Capital invested by funds: $116B → $116B (-$569M)

24% less call options, than puts

Call options by funds: $2B | Put options by funds: $2.62B

Holders
1,263
Holders Change
+74
Holders Change %
+6.22%
% of All Funds
36.28%
Holding in Top 10
164
Holding in Top 10 Change
+52
Holding in Top 10 Change %
+46.43%
% of All Funds
4.71%
New
163
Increased
527
Reduced
461
Closed
83
Calls
$2B
Puts
$2.62B
Net Calls
-$624M
Net Calls Change
+$552M
Name Holding Trade Value Shares
Change
Change in
Stake
IMS
901
Index Management Solutions
Pennsylvania
$919K -$157K -2,019 -15%
SFA
902
Sequoia Financial Advisors
Ohio
$917K
FIM
903
Freedom Investment Management
Connecticut
$902K +$99K +1,272 +13%
TI
904
Turner Investments
Pennsylvania
$893K -$5.24M -67,345 -86%
Acadian Asset Management
905
Acadian Asset Management
Massachusetts
$891K -$290K -3,727 -26%
AWA
906
AmeriServ Wealth Advisors
Pennsylvania
$881K +$217K +2,783 +35%
Grantham, Mayo, Van Otterloo & Co (GMO)
907
Grantham, Mayo, Van Otterloo & Co (GMO)
Massachusetts
$879K -$39.4M -506,346 -98%
RG
908
Rathbones Group
United Kingdom
$877K +$49.8K +640 +6%
NME
909
Notis-McConarty Edward
$871K -$38.9K -500 -5%
AHB
910
Abner Herrman & Brock
New Jersey
$869K
CK
911
Carnick & Kubik
Colorado
$867K +$814K +10,460 New
CCM
912
Condor Capital Management
New Jersey
$857K +$805K +10,342 New
RBC
913
Ronald Blue & Co
Georgia
$855K -$1.09K -14 -0.1%
LPT
914
Legacy Private Trust
Wisconsin
$854K +$802K +10,300 New
KFS
915
KMS Financial Services
Washington
$849K +$95.7K +1,229 +14%
AWS
916
Aris Wealth Services
Pennsylvania
$843K +$7.71K +99 +1%
TSWM
917
Triangle Securities Wealth Management
North Carolina
$841K +$789K +10,140 New
SI
918
SII Investments
Wisconsin
$836K +$128K +1,646 +19%
BRWM
919
B. Riley Wealth Management
Tennessee
$835K -$431K -5,535 -35%
NAMP
920
NorthStar Asset Management (Pennsylvania)
Pennsylvania
$834K +$783K +10,055 New
NERM
921
New England Research & Management
Illinois
$833K +$471K +6,050 +151%
USGIU
922
U.S. Global Investors (USGI)
Texas
$829K +$778K +10,000 New
CAM
923
Columbia Asset Management
Michigan
$823K +$202K +2,600 +35%
RJT
924
Raymond James Trust
Florida
$821K -$36.3K -466 -4%
PP
925
Paloma Partners
Connecticut
$804K +$490K +6,300 +185%

GILD Hedge Fund Activity: Q2 2014 in Review

1,263 of the 3,481 institutional investors tracked by Wall St. Rank reported a position in Gilead Sciences (GILD) for Q2 2014, worth a combined $116B — down 0.49% from $116B a quarter earlier.

Buyers outnumbered sellers: 163 funds opened new GILD positions and 83 closed out — a net gain of 80 holders — while 527 added to existing stakes and 461 trimmed.

The largest buyer was Capital Research Global Investors, adding an estimated $1.16B. The largest seller was BNP Paribas Financial Markets, cutting an estimated $3.85B.

  • 1,263 institutional investors held Gilead Sciences (GILD) as of Q2 2014, up from 1,189 in Q1 2014.
  • Funds reported $116B of Gilead Sciences stock for Q2 2014, down 0.49% quarter-over-quarter.
  • 163 funds opened new Gilead Sciences positions in Q2 2014 and 83 closed out, a net change of +80 holders.
  • The largest Gilead Sciences buyer in Q2 2014 was Capital Research Global Investors, an estimated $1.16B added.
  • The largest Gilead Sciences seller in Q2 2014 was BNP Paribas Financial Markets, an estimated $3.85B sold.

Based on aggregated 13F filings for Q2 2014.